ArticleClinicoEconomics and outcomes research : CEOR2026
Effect of Drug Cost-Exemption Policy on Treatment Outcomes in Multidrug-Resistant Tuberculosis Patients in Guangxi Zhuang Autonomous Region, China: A Nested Case-Control Study.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most effective patient support interventions in low- and middle-income countries remain a research gap in World Health Organization consolidated guidelines on tuberculosis. We explored the impact of a partial drug cost-exemption policy (including cycloserine, moxifloxacin, linezolid, and clofazimine) implemented in Guangxi Zhuang Autonomous Region, China, on treatment outcomes among local multidrug-resistant tuberculosis (MDR-TB) patients. Methods: This case-control study enrolled 424 MDR-TB patients receiving anti-TB treatment between 2020 and 2022 in Guangxi Zhuang Autonomous Region. Data on demographics, treatment regimen, drug cost-exemption status, and adverse reactions were extracted from electronic medical records. Multivariable logistic regression analysis was used to identify factors associated with successful treatment outcomes. Results: Among the 424 enrolled MDR-TB patients, 212 (50.0%) had successful treatment outcomes, including 79 cured (18.6%) and 133 treatment completed (31.4%). Unfavorable outcomes were observed in 212 patients (50.0%), comprising 190 lost to follow-up (44.8%), 19 deaths (4.5%), and 3 treatment failures (0.7%). Multivariable analysis revealed that female sex (aOR = 2.99, 95% CI: 1.55-5.78), absence of adverse drug reactions (aOR = 11.58, 95% CI: 3.81-35.18), and receiving drug cost-exemption (aOR = 37.47, 95% CI: 10.97-127.96) were associated with favorable treatment outcomes. Furthermore, receiving an increasing number of exempted drugs was progressively associated with higher treatment success. Compared to one drug exemption, the aOR for successful outcomes was 3.24 (95% CI: 2.16-4.87) for two-drug cost-exemption and 5.13 (95% CI: 2.73-9.65) for three-drug cost-exemption. Conclusion: This nested case-control study demonstrates that implementing drug cost-exemption support policy is associated with significantly improved MDR-TB treatment success rates in resource-limited, high-burden settings in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.